Neximmune Total Stockholder Equity vs Non Current Assets Total Analysis
| NEXI Stock | USD 3.34 0.10 2.91% |
Neximmune financial indicator trend analysis is infinitely more than just investigating Neximmune recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neximmune is a good investment. Please check the relationship between Neximmune Total Stockholder Equity and its Non Current Assets Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.
Total Stockholder Equity vs Non Current Assets Total
Total Stockholder Equity vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neximmune Total Stockholder Equity account and Non Current Assets Total. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Neximmune's Total Stockholder Equity and Non Current Assets Total is 0.53. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Neximmune, assuming nothing else is changed. The correlation between historical values of Neximmune's Total Stockholder Equity and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Neximmune are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Total Stockholder Equity i.e., Neximmune's Total Stockholder Equity and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.53 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Neximmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neximmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.As of now, Neximmune's Selling General Administrative is increasing as compared to previous years. The Neximmune's current Enterprise Value Over EBITDA is estimated to increase to 0.03, while Issuance Of Capital Stock is projected to decrease to 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 861.4K | 576.7K | 1.0M | 702.8K | Interest Income | 52.5K | 664.4K | 973.3K | 1.0M |
Neximmune fundamental ratios Correlations
Click cells to compare fundamentals
Neximmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neximmune fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 13.7M | 11.3M | 91.0M | 43.1M | 8.6M | 8.2M | |
| Other Current Liab | 1.9M | 2.5M | 6.2M | 7.4M | 3.7B | 3.9B | |
| Total Current Liabilities | 3.0M | 27.0M | 7.2M | 10.3M | 5.1M | 4.8M | |
| Total Stockholder Equity | 10.6M | (15.8M) | 83.8M | 32.3M | 3.5M | 3.3M | |
| Net Tangible Assets | (43.0M) | (69.4M) | 83.8M | 32.3M | 37.1M | 39.0M | |
| Property Plant And Equipment Net | 2.6M | 2.9M | 4.4M | 5.4M | 1.4M | 1.3M | |
| Net Debt | 44.5M | 14.1M | (30.3M) | (33.6M) | (3.1M) | (3.0M) | |
| Retained Earnings | (47.7M) | (77.6M) | (127.7M) | (190.2M) | (222.6M) | (211.5M) | |
| Accounts Payable | 1.2M | 2.8M | 1.0M | 2.4M | 1.3M | 1.8M | |
| Cash | 9.1M | 5.0M | 30.3M | 34.6M | 3.2M | 3.0M | |
| Non Current Assets Total | 2.7M | 2.9M | 4.8M | 5.7M | 3.2M | 3.9M | |
| Non Currrent Assets Other | 103.6K | 23.4K | 324.1K | 265.0K | 1.8M | 1.9M | |
| Cash And Short Term Investments | 10.1M | 5.0M | 81.8M | 34.6M | 4.6M | 4.4M | |
| Common Stock Shares Outstanding | 900.9K | 910.3K | 913.2K | 962.4K | 1.0M | 1.9M | |
| Liabilities And Stockholders Equity | 13.7M | 11.3M | 91.0M | 43.1M | 8.6M | 8.2M | |
| Other Current Assets | 833.2K | 78.5K | 99.2K | 2.7M | 215.2K | 204.5K | |
| Other Stockholder Equity | 4.7M | 8.2M | (90.8B) | 222.5M | 226.1M | 237.4M | |
| Total Liab | 3.1M | 27.1M | 7.3M | 10.8M | 5.1M | 4.8M | |
| Net Invested Capital | (43.0M) | (50.3M) | 83.8M | 32.3M | 3.5M | 3.7M | |
| Property Plant And Equipment Gross | 2.6M | 2.9M | 6.7M | 5.4M | 3.0M | 4.1M | |
| Total Current Assets | 11.0M | 8.4M | 86.3M | 37.4M | 5.4M | 5.1M | |
| Net Working Capital | 8.0M | (18.6M) | 79.1M | 27.0M | 316.7K | 300.9K | |
| Property Plant Equipment | 2.6M | 2.9M | 4.4M | 5.4M | 6.2M | 3.7M |
Currently Active Assets on Macroaxis
When determining whether Neximmune offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neximmune's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neximmune Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neximmune Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Neximmune Stock analysis
When running Neximmune's price analysis, check to measure Neximmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neximmune is operating at the current time. Most of Neximmune's value examination focuses on studying past and present price action to predict the probability of Neximmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neximmune's price. Additionally, you may evaluate how the addition of Neximmune to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Neximmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neximmune. If investors know Neximmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neximmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (30.82) | Return On Assets (0.71) | Return On Equity (1.81) |
The market value of Neximmune is measured differently than its book value, which is the value of Neximmune that is recorded on the company's balance sheet. Investors also form their own opinion of Neximmune's value that differs from its market value or its book value, called intrinsic value, which is Neximmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neximmune's market value can be influenced by many factors that don't directly affect Neximmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neximmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neximmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neximmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.